The central question facing Walgreens was never whether disruption was coming. It was whether the organization could recognize that the business model it had perfected over seven decades was the very thing that made it vulnerable to the forces reshaping it. It could not. The result is an important example of incumbent decline. Walgreens went from a $106 billion market capitalization to a $10 billion private equity acquisition in a single decade. No industry rival beat it at its own game. Challengers from inside and outside the retail pharmacy sector made that game progressively less relevant.
The $96 billion destruction of shareholder value is not primarily a story of operational failure, though operations deteriorated badly in the final years. It is a story of strategic misdiagnosis, about an organization that consistently answered the question “how do we grow?” when the harder, more important question was “is the model we are growing still the right one?”
The Threats to Walgreens’ Business Model
Walgreens built its dominance on two postwar trends: the rise of the automobile and the growing cost burden of healthcare. Large-format pharmacies at high-traffic intersections captured prescription customers who, once inside, were primed for impulse purchases across over-the-counter medicines, household products, and convenience items. Prescription revenue provided healthy margins, and front-of-store traffic built on top of it. For decades, this formula was self-reinforcing. More locations meant more foot traffic. More foot traffic meant more prescriptions filled and more impulse purchases.
The structural threat came from a shift in the primary buyer, not from a competitor operating the same model more effectively. As healthcare costs became a commercial and political priority, prescription payments shifted from individual patients to managed care organizations and pharmacy benefit managers (PBMs), acting as aggregators on behalf of insurance companies and employers. PBMs leveraged their access to a large, covered membership in exchange for lower reimbursement rates per prescription.
The consequences were measurable and compounding. Prescription margins declined 30 to 40 percent between 2010 and 2020 as PBMs tightened their negotiating terms and redirected patients toward mail-order and specialty pharmacy alternatives. When Walgreens challenged Express Scripts’ demand for a lower reimbursement rate, Express Scripts removed Walgreens from its approved pharmacy network. The resulting revenue decline, at approximately 20 to 30 percent, was swift and severe enough that Walgreens accepted the terms. The margin engine that funded the entire retail model was structurally compromised and would not recover through negotiating leverage alone. A different model was required.
Walgreens’ Response: Do More of the Same
What followed was a significant investment in the existing model rather than a departure from it. Walgreens expanded its store footprint to a peak of approximately 8,700 locations between 2018 and 2019. It acquired a 45 percent stake in Alliance Boots in 2012, then completed the full merger in 2014, thus creating Walgreens Boots Alliance. This sprawling international operation added complexity without resolving the core margin problem. It attempted to acquire Rite Aid in 2015 but was blocked by the Federal Trade Commission on antitrust grounds. Then, in 2017, it purchased approximately 1,900 Rite Aid stores as that chain attempted to avoid bankruptcy.
Buying a failing competitor’s stores when the underlying business model was deteriorating is the clearest evidence of Y-axis thinking: a company doing more of the same rather than looking for ways to change the business. Each move made sense within the logic of the existing model. Yet none of them addressed the structural deterioration in the traditional retail-pharmacy-chain business model.
Meanwhile, the competitive attacks on Walgreens did not come just from other pharmacy chains. They also came from challengers from outside the sector and with different business models. In 2018, Amazon acquired PillPack, a mail-order pharmacy that pre-sorted medications by dose and delivered them to patients’ homes, for $783 million. The move signaled Amazon’s intent to compete with Walgreens on convenience and redesign the patient experience by moving the dispensing moment from the store to the patient’s home. In a prescription drug market approaching $500 billion annually, where 60 percent of patients take at least one chronic medication daily, that repositioning had long-term implications that Walgreens’ 8,700-store footprint could not offset. Big-box retailers including Walmart and Costco were simultaneously capturing pharmacy sales from existing shopping trips to their stores, eliminating the need for a dedicated pharmacy trip for a growing segment of customers. Digital pharmacy startups like Capsule were targeting urban markets with same-day delivery and a technology-native experience that Walgreens’ aging store infrastructure could not replicate.
None of these moves were intended to out-Walgreens Walgreens. All of them helped to make Walgreens less necessary for a growing share of patients.
Walgreens’ Unsuccessful X-Axis Move
Walgreens eventually recognized that the pharmacy retail model was insufficient on its own. It decided to expand into healthcare delivery, acquiring VillageMD, CityMD, and Summit Health. This series of transactions committed billions of dollars to co-locating primary care clinics within and adjacent to its store network. The strategic premise behind the deals: if the in-store pharmacy visit was becoming less compelling as a standalone destination, anchor it to a primary care relationship to drive both clinical and retail traffic.
The strategy boiled down to: build it, and patients will come. They did not, at least not in sufficient numbers or fast enough to justify the capital deployed. Walgreens lacked the clinical reputation, the physician relationships, or the coordinated care infrastructure needed to attract patients away from established primary care practices and health systems. Healthcare delivery is a trust relationship built over years of clinical contact. The assumption that pharmacy foot traffic would translate into primary care utilization underestimated how patients think differently about filling a prescription and choosing a doctor. It also underestimated how much capital, patience, and operational capability it takes to build a viable primary care network in a market already served by deeply entrenched providers. In March 2024, Walgreens took a $5.8 billion write-down and announced the closure of 160 VillageMD clinics.
The acquisitions and the Boots Alliance merger loaded Walgreens with debt, limiting its financial flexibility and ability to maneuver. The opioid crisis compounded the damage. Walgreens, alongside other major pharmacy chains, faced multi-billion-dollar settlements over allegations that it had failed to adequately police suspicious prescriptions during the worst years of the epidemic. The financial cost was substantial; the reputational damage (particularly with the regulators, health systems, and patients) was arguably greater.
Between 2019 and 2023, Walgreens cycled through four chief executives. Each new leader reset organizational priorities and signaled to the market that the previous direction lacked conviction. For an organization attempting a multi-year transformation while managing deteriorating core business performance, that degree of leadership discontinuity was fatal.
What CVS Did Differently
The contrast with CVS Health is instructive because both companies faced identical external conditions: the same managed care and PBM margin pressure, the same Amazon and e-commerce threat, the same shifting patient behaviors, and the same regulatory environment. CVS made materially different strategic choices.
In 2018, CVS acquired Aetna for $69 billion. This transaction expanded CVS’ assets from retail pharmacy and PBM management into insurance underwriting. This was not a Y-axis move. It was a fundamental repositioning of where in the healthcare value chain CVS would compete. By owning both the payer relationship and the pharmacy dispensing channel, CVS created a vertically integrated model with structural incentives to manage total healthcare cost — the same objective the PBMs had been pursuing on behalf of their insurance clients. In 2023, CVS acquired Oak Street Health to build a Medicare primary care network, targeting the rapidly growing population of older adults transitioning from commercial insurance to government-funded coverage. CVS has its own challenges, including uneven financial performance and antitrust claims from some members of Congress. But its strategic choices were sound. They positioned it to compete for a different kind of value. Unlike Walgreens, it focused on the economics of managing a patient’s total health rather than the margin on a prescription fill.
The contrast between Walgreens’ and CVS’ strategic choices is not a matter of resources or market intelligence. Both had access to the same signals. But CVS sought to climb up the value chain at considerable cost and risk, including cannibalizing parts of its existing model in pursuit of a different one. Walgreens chose to double down on its existing model until it was forced to try something different.
The Insurgent Question Every Incumbent Should Ask
Walgreens received signals that its business model was under structural pressure long before the final decline accelerated. The Express Scripts ultimatum in 2012. Amazon’s acquisition of PillPack in 2018. The decade-long compression of prescription margins. The organization received all these signals and, each time, it responded with the same answer: more scale, more stores, more acquisitions within the deteriorating model.
Scale is not dangerous, and incumbency is not a death sentence. CVS faced the same disruption as Walgreens and made meaningfully different choices. What separates companies that navigate disruption from those that don’t is the willingness to redesign the business to align with changes in customer expectations and market conditions.
For leaders, the relevant questions are not about Walgreens. They are about the signals you are currently seeing in your own industry. Which core assumptions about how customers choose, how margins are generated, and where your competitive advantage comes from are being challenged? And are you responding with the same answer or a genuinely different one?
Walgreens had the resources, the market presence, and the time to ask those questions. It consistently chose not to. The result is a $96 billion lesson in the cost of relying on outdated assumptions and an old playbook.